Skip to main content
. Author manuscript; available in PMC: 2015 May 1.
Published in final edited form as: Cancer Res. 2014 May 1;74(9):2391–2401. doi: 10.1158/0008-5472.CAN-13-2652

Figure 5.

Figure 5

Application of therapies to the computational model of the metastatic prostate cancer bone microenvironment. A–C, The impact of standard of care therapies on the host microenvironment cell numbers in prostate to bone metastases was assessed in simulations where no therapy was applied (Control; A), Bisphosphonates at a dosing of 4mg/5ml intravenous (Bisphosphonate; B) or RANKL targeted therapy (Anti-RANKL; C) at a dose of 120mg/1.7ml intravenous were applied at approximately 80 days post metastasis (Rx On). D–E, The impact of placebo control and standard of care therapies on tumor volume (D) and bone volume (E) over time.